Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive: An Open-Label, Randomized, Crossover Study of Estradiol Valerate/Dienogest versus Ethinylestradiol/Levonorgestrel
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A novel estradiol-based combined oral contraceptive (COC) is currently available in many countries worldwide, including Europe and the US. Based on previous studies, it is expected that this estradiol-based COC will have a reduced hepatic effect compared with COCs containing ethinylestradiol with regard to proteins controlling the hemostatic balance. OBJECTIVE: The aim of this study was to compare the hemostatic effects of the estradiol valerate/dienogest COC with a monophasic low-estrogen dose COC containing ethinylestradiol/levonorgestrel. STUDY DESIGN: Healthy women aged 18-50 years were randomized to receive a COC containing estradiol valerate/dienogest (2 days estradiol valerate 3 mg, 5 days estradiol valerate 2 mg/dienogest 2 mg, 17 days estradiol valerate 2 mg/dienogest 3 mg, 2 days estradiol valerate 1 mg, 2 days placebo) or ethinylestradiol 0.03 mg/levonorgestrel 0.15 mg in a crossover study design. Women received each treatment for three cycles, with two washout cycles between treatments. The primary efficacy variables were the intra-individual absolute changes in prothrombin fragment 1 + 2 and D-dimer from baseline to cycle three. RESULTS: Data from 29 women were assessed. Intra-individual absolute changes in prothrombin fragment 1 + 2 and D-dimer from baseline to cycle three were less pronounced with estradiol valerate/dienogest than with ethinylestradiol/levonorgestrel. CONCLUSION: The novel COC containing estradiol valerate/dienogest had similar or less pronounced effects on hemostatic parameters than ethinylestradiol/levonorgestrel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Rosing, J., Tans, G., Nicolaes, G. A. F., Thomassen, M. C. L. G. D., Van Oerle, R., Van DerPloeg, P. M. E. N., Heijnen, P., Hamulyak, K., & Hemker, H. C. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.192707.x · Cited by 325
Comparison of pharmacodynamic properties of various estrogen formulations
Mashchak, C. A., Lobo, R. A., Dozono-Takano, R., Eggena, P., Nakamura, R. M., Brenner, P. F., & Mishell, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90218-6 · Cited by 316
The pharmacological profile of dienogest
Oettel, M., Breitbarth, H., Elger, W., Gräser, T., Hübler, D., Kaufmann, G., Moore, C., Patchev, V., Römer, W., Schröder, J., et al. (1999) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189909085259 · Cited by 61 · cited 1×
“However, changes observed with COCs reflect not only influences of the estrogen component, but also those of the progestogen component; indeed, progestogen can affect the binding of testosterone or cortisol to transport proteins([33]) and the clearance time from serum.”
Background
Cited by
Hormonal contraception and thrombosis
Sitruk-Ware, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.08.039 · Cited by 79
Systemic hormonal contraception and risk of venous thromboembolism
Heikinheimo, O., Toffol, E., Partonen, T., But, A., Latvala, A., & Haukka, J. (2022) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14384 · Cited by 58
Fruzzetti, F., Trémollieres, F., & Bitzer, J. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.662547 · Cited by 56
Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism
Bastianelli, C., Farris, M., Rosato, E., Brosens, I., & Benagiano, G. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1271708 · Cited by 50
Metabolic impact of combined hormonal contraceptives containing estradiol
Grandi, G., Napolitano, A., & Cagnacci, A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1190832 · Cited by 50
Metadata
- Authors
- Klipping, C., Duijkers, I., Parke, S., Mellinger, U., Serrani, M., & Junge, W.
- Venue
- Drugs in R & D
- Published
- 2011-06
- Volume
- 11
- Issue
- 2
- Pages
- 159-170
- ISSN
- 1174-5886 (ISSN-L)
- 1179-6901
- OpenAlex
- W2081805706
- Cited by
- 90
- References
- 4
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive: An Open-Label, Randomized, Crossover Study of Estradiol Valerate/Dienogest versus Ethinylestradiol/Levonorgestrel. https://app.cochat.ai/papers/10.1007/bf03259805
- The paper
- Klipping, C., Duijkers, I., Parke, S., Mellinger, U., Serrani, M., & Junge, W. (2011). Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive: An Open-Label, Randomized, Crossover Study of Estradiol Valerate/Dienogest versus Ethinylestradiol/Levonorgestrel. Drugs in R & D. https://doi.org/10.1007/bf03259805
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.